Naming
Biosimilars, although highly similar to the reference product, may not be highly similar to each other. In Canada, biologic drugs, including biosimilars, are identified by brand name, common (non-proprietary name) and DIN.
However, there are calls for a naming convention that distinguishes between biologic drugs that share the same common name to facilitate accurate prescribing and pharmacovigilance. Health Canada has supported WHO efforts to develop a global naming convention with a “Biological Qualifier” that would be applicable to all biological substances.
In February 2019, Health Canada announced that biologic drugs, including biosimilars, will be identified by the following:2
It is recommended that both the brand name and non-proprietary name should be used throughout the medication process so that biologics with the same non-proprietary name can be distinguished.2
References: 1. Parker C. Health Canada. Regulation of biosimilars: challenges and opportunities. https://www.conferenceboard.ca/docs/default-source/conf-pres-public/17-0064_p3_parker.pdf?sfvrsn=0. Published April 2017. Accessed September 6, 2018.
2. Health Canada. Notice to Stakeholders – Policy Statement on the Naming of Biologic Drugs. Accessed September 18, 2019. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-notice-to-stakeholders-drugs-naming-of-biologics.html.
